MRNAModerna, Inc. NASDAQ
Moderna, Inc. 200 Technology Square Cambridge, MA 02139 United States https://www.modernatx.com/Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on vaccine technologies based on messenger RNA. Moderna's vaccine platform inserts synthetic nucleoside-modified messenger RNA into human cells using a coating of lipid nanoparticles.
- CEO: Stéphane Bancel
- Employees: 1,300
- Sector: Healthcare
- Industry: Biotechnology
Latest news about the MRNA
- 30 states likely to miss President Biden’s July 4 vaccination goal, and Brazil death toll tops 500,000
The U.S. is getting close to President Joe Biden's goal of having 70% of the adult population receive at least one vaccine dose by July 4, but at least 30 states will likely miss that goal and a handful may not reach it by year-end.View More →
- Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?
The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.View More →
- 5 Ultra-Popular Stocks Wall Street Views as Overvalued
Generally speaking, it pays to be bullish on Wall Street. Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells.View More →
- Covid-19 Booster Shots: When Might You Need One and Why?
Companies are working on coronavirus booster shots, as some early studies suggest antibody levels against Covid-19 wane with time, making boosters more necessary. We explore what that means for individual consumers. Illustration: Laura Kammermann/The Wall Street JournalView More →
- SoftBank, Nomura Tapped to Offer Moderna Shots for Employees
(Bloomberg) -- In a country where workplaces play an outsized role in people’s lives, Japan is betting that enlisting its largest corporations to roll out Covid-19 vaccines will add fuel to a much-scrutinized inoculation drive.Still grappling with a rollout that’s deployed only enough doses to cover 11% of the population, the Japanese government is allowing its biggest corporate brand names and employers like Toyota Motor Corp., SoftBank Group Corp., and Nomura Holdings Inc. to administer shotsView More →
- U.S. Warns China on Covid Origin; Cruise Sets Sail: Virus Update
(Bloomberg) -- China will risk international isolation if it fails to allow a “real” investigation on its territory into the origins of the virus that caused the pandemic, U.S. National Security Adviser Jake Sullivan said. President Joe Biden is traveling to North Carolina on Thursday to encourage more Americans to get vaccinated.Russia, Germany and Portugal reported an expanding spread of the highly transmissible delta variant that first appeared in India. Scott Gottlieb, a former head of the UView More →
- If You Invested $10,000 in Ocugen in December, This Is How Much You Would Have Today
You might not have heard of Ocugen (NASDAQ: OCGN) a year ago. Ocugen soared more than 760% from January through a peak in February. The company partnered with India's Bharat Biotech to co-commercialize Bharat's near-to-market coronavirus vaccine in the U.S. So, if you were one of the early believers in this highflier, you watched your investment skyrocket.View More →
- Pfizer's COVID Vaccine Is Even More Amazing Than You Think
When they did -- thanks to Pfizer, BioNTech, and Moderna -- the results were much better than most had hoped for. The Pfizer-BioNTech drug -- now marketed as Comirnaty -- was the first to share phase 3 data. Moderna followed two weeks later with its own impressive results.View More →
- What to Make of the CDC's Latest Efficacy Data on Pfizer's and Moderna's COVID Vaccines
It hasn't been a secret that the COVID-19 vaccines developed by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are highly effective. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should make of the latest CDC data.View More →
- Why Moderna, Illumina, or Meituan Could Be the Next Tesla Stock
Baillie Gifford’s Tom Slater invests in companies and CEOs with long-term vision, irrespective of short-term market moves.View More →
- Moderna Stock Retreats Slightly On Vaccine Worries — Is It A Buy Right Now?
Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride. Is Moderna stock a buy now?View More →
- Moderna to add 155 more people in high-tech manufacturing jobs in Massachusetts in 2021
Moderna Inc. said Friday it remains committed to creating jobs in Massachusetts and will hire at least 155 more people for high-tech manufacturing roles this year. The biotech, which has an emergency use authorization for its COVID-19 vaccine, said it has almost doubled its workforce in the Bay State in the past year to about 1,500 workers from 830 as of March 31, 2020. The company is still expanding in Norwood and Cambridge, it said in a statement. In Norwood, a production and lab space has beeView More →
- Moderna Reaffirms Commitment to Job Creation in Massachusetts
CAMBRIDGE, Mass., Jun 18, 2021--Moderna reaffirms commitment to job creation in Massachusetts.View More →
- 12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer
The European Commission already has signed an advance purchase agreement for as many as 405 million doses from the company. "Demonstrating high efficacy in this unprecedented broad diversity of variants is challenging," CureVac CEO Franz-Werner Haas said when reporting the interim trial analysis.View More →
- Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine
Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective . But Curevac's chief financial officer, Pierre Kemula, said the company hopes its candidate can still be of use, when a final analysis is done, with that data just two or three weeks away. "We need to look at the data and see, OK, what would be the best value, how we can place this vaccinView More →
- The Most Important of Moderna's 3 Catalysts Last Week
Moderna (NASDAQ: MRNA) has been quite busy. The company announced three positive developments last week, all of which have the potential to boost sales for its COVID-19 vaccine. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these is the most important catalyst for the biotech stock.View More →
- How Does Novavax Stack Up Against Today's Vaccine Leaders?
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have remained a step ahead of most potential coronavirus vaccine rivals. Novavax (NASDAQ: NVAX) plans to submit its coronavirus vaccine candidate for emergency authorization in various countries including the U.S. in the third quarter. Now the question is whether Novavax has what it takes to join leaders Pfizer and Moderna at the top.View More →
- Why BioNTech, Moderna, and Novavax Stocks Sank This Week
Shares of BioNTech (NASDAQ: BNTX) were down 10.2% for the week, as of the market close on Thursday. Moderna (NASDAQ: MRNA) stock fell 7.5%, and Novavax (NASDAQ: NVAX) tumbled 14.2%. The decline for Novavax might be the most puzzling.View More →
- UPDATE 1-Taiwan says 240,000 COVID-19 Moderna doses to arrive on Friday
A further 240,000 COVID-19 vaccine doses from Moderna Inc will arrive in Taiwan on Friday afternoon, Deputy Minister of the Interior Chen Tsung-yen said, boosting the island's slow vaccination programme. Only around 5% of Taiwan's 23.5 million people have received at least one shot so far, with orders delayed by global shortages as the island deals with a spike in domestic infections. Taiwan has already received and has started administering 150,000 Moderna shots, and has around 5 million on order.View More →
- The latest on the Covid-19 pandemic in the U.S.
Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joined Yahoo Finance to discuss the latest on covid.View More →